Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

2372.00

Share Price

2327.00

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 81.76%
Worldwide Healthcare (Ordinary Share) NAV 82.61%
FTSE World 58.77%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 2286.8 -3.6% 2372.00 2344.00
27 Mar
110% 0.72%

Discrete performance % over

Fund / BenchmarkApr '14
Mar '15
Apr '15
Mar '16
Apr '16
Mar '17
Worldwide Healthcare (Ordinary Share) Price48.80-8.7933.92
Worldwide Healthcare (Ordinary Share) NAV55.10-8.8729.20
FTSE World19.35-0.1133.18

Discrete performance over

Discrete Performance

Top 10 Holdings

Wright Medical Group, Inc. 4.54%
Merck & Co. Inc. 4.44%
Boston Scientific, Inc. 4.14%
Alexion Pharmaceuticals, Inc. 3.75%
Eli Lilly & Co. 3.55%
Incyte Corporation 3.45%
Biogen Idec Inc., 3.36%
HCA Holdings Inc 3.06%
Roche Holding AG 2.96%
Nippon Shinyaku Co Ltd 2.57%

Sectors weighting

Pharmaceuticals 101.30%
Net Current Assets -1.30%

Regional weighting

North America Region 70.00%
Europe Developed ex-UK 16.00%
Japan 7.00%
Other Countries 4.00%
Asia exc Japan 4.00%
UK 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 2327.00
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 47
  • Market Capital (£M) 1064.99
  • Gross Assets (£M) 1215.71
  • Net Assets (£M) 1103.30
  • TER (%) 0.96
  • Historic Dividend Yield (%) 0.72
  • Last AGM 21 Sep 2016
  • Next AGM 21 Sep 2017
  • Last Annual Report Date 24 Jun 2016
  • Next due Report Date 31 Mar 2017
  • Next due Report Type A/R
  • Objective:

    To invest worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.

  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a.. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.